Developing E-Plasters to enable self-management of rapid and complete wound healing

有效的伤口愈合是一个巨大的未得到满足的临床需求。伤口给医疗系统和社会带来了巨大的经济成本，但人们往往没有意识到这种影响。国际糖尿病联合会显示，全球有超过4.6亿糖尿病患者，预计到2045年，这一数字将上升到7亿。糖尿病足溃疡通常是传染性的，有时患者可能会截肢。然而，伤口往往缺乏优先权和投资。伤口不被认为是一种疾病，慢性伤口患者被分配到长期的伤口管理中，由于存在减缓伤口进展的治疗方法，但很少能完全扭转问题，所以他们只是“忍受”。因此，确实需要解决这个问题。我们的目标是通过我们基于生物材料和生物化学的创新，实现更好的生活质量，并促进NHS显著节省成本。这个项目将使我们能够开发E-石膏(R)，使用个性化的、直观的、以患者为中心的治疗来实现慢性伤口的自我管理，以快速而彻底地治愈慢性伤口。并确保急性伤口迅速愈合，不会出现并发症。

Efficacious wound healing is a huge unmet clinical need. Wounds pose a significant economic cost to the healthcare system, and the society, but the impact often under-recognised.International Diabetes Federation shows, more than 460 million people are living with diabetes worldwide and by 2045 this number is expected to rise to 700 million. Diabetic foot ulcers usually turn out to be infectious and at times patient may end up with amputations. Yet, wounds can often lack priority, and investment.Wounds are not considered a disease, and chronic wound patients are assigned to long term wound management, and just "live with it" as therapies exist that slow down the advancement of wounds, but rarely reverse completely the problem.Thus there is a real need to address this.We aim to enable a better quality of life and facilitate significant cost savings to the NHS through our innovations based on biomaterials and biolectricity.This project will enable us to develop E-plaster(r), to enable self-management of chronic wounds using personalised, intuitive, patient centric therapy to rapidly and completely heal chronic wounds, and to ensure that acute wounds heal rapidly without acquiring complications.